GlassScriptPrepare for your visit
Daniel P Barton
Nephrology (Internal Medicine) · Canfield, OH · NPI 1063488096
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$3,200.56
in general payments reported to CMS, 2019-2025 · $842 in 2025
The $842 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Who reported paying
General payments only, top 6 by amount.
- Bayer Healthcare Pharmaceuticals INC. $638.45
- Amgen INC. $355.63
- Otsuka America Pharmaceutical, INC. $297.36
- Vifor Pharma, INC. $250.00
- Travere Therapeutics, INC. $228.66
- Astrazeneca Pharmaceuticals LP $168.52
Drugs and devices associated with these payments
Kerendia Tavneos Renal - Pd Fabhalta Krystexxa Jynarque Veltassa Vanrafia Farxiga Tarpeyo Jardiance Ibsrela
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Daniel Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/139316/daniel-p-barton